

FORM PTO-1390
REV. 2/01

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

TRANSMITTAL LETTER TO THE UNITED STATES
DESIGNATED/ELECTED OFFICE (DO/EO/US)
CONCERNING A FILING UNDER 35 U.S.C. 371ATTORNEY'S DOCKET NUMBER
01142.0102U.S. APPLICATION NO.
(If known, see 37 CFR 1.5)

09/786033

INTERNATIONAL APPLICATION NO.

PCT/US99/20013

INTERNATIONAL FILING DATE

September 1, 1999

PRIORITY DATE CLAIMED

September 1, 1998

TITLE OF INVENTION

METHODS FOR IMPROVING THE FUNCTION OF HETEROLOGOUS G
PROTEIN-COUPLED RECEPTORS

APPLICANT(S) FOR DO/EO/US


Mark Henry PAUSCH and Jurgen WESS

Applicant(s) herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:

1. ☒ This is a **FIRST** submission of items concerning a filing under 35 U.S.C. 371.
2. ☐ This is a **SECOND** or **SUBSEQUENT** submission of items concerning a filing under 35 U.S.C. 371.
3. ☐ This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (21) indicated below.
4. ☒ The US has been elected by the expiration of 19 months from the priority date (Article 31).
5. ☒ A copy of the International Application as filed (35 U.S.C. 371 (c)(2)).
 - a. ☒ is attached hereto (required only if not communicated by the International Bureau).
 - b. ☒ has been communicated by the International Bureau.
 - c. ☐ is not required, as the application was filed with the United States Receiving Office (RO/US).
6. ☐ An English language translation of the International Application as filed (35 U.S.C. 371 (c)(2)).
 - a. ☐ is attached hereto.
 - b. ☐ has been previously submitted under 35 U.S.C. 154 (d)(4).
7. ☒ Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371 (c)(3)).
 - a. ☐ are attached hereto (required only if not communicated by the International Bureau).
 - b. ☐ have been communicated by the International Bureau.
 - c. ☐ have not been made; however, the time limit for making such amendments has NOT expired.
 - d. ☒ have not been made and will not be made.
8. ☐ An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371 (c)(3)).
9. ☐ An oath or declaration of the inventor(s) (35 U.S.C. 371 (c)(4)).
10. ☒ Annexes of the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371 (c)(5)).

Items 11 to 20 below concern document(s) or information included:

11. ☒ Information Disclosure Statement under 37 CFR 1.97 and 1.98.
12. ☐ An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.
13. ☐ A **FIRST** preliminary amendment.
14. ☐ A **SECOND** or **SUBSEQUENT** preliminary amendment.
15. ☐ A Substitute specification.
16. ☐ A change of power of attorney and/or address letter.
17. ☒ A sequence listing containing 7 pages and and Statement Accompanying Sequence Listing (1 page).
18. ☐ A second copy of the published international application under 35 U.S.C. 154 (d)(4).
19. ☐ A second copy of the English language translation of the international application 35 U.S.C. 154 (d)(4).
20. ☒ Other items or information:
 - a. ☒ Copy of cover page of International Publication No. WO00/12705
 - b. ☐ Copy of Notification of Missing Requirements.
 - c. ☐



U.S. APPLICATION NO. (if known, see 37 CFR 1.55)

09/786033

INTERNATIONAL APPLICATION NO.
PCT/US99/20013ATTORNEY'S DOCKET NUMBER
01142.010221. ☒ The following fees are submitted:**BASIC NATIONAL FEE (37 CFR 1.492 (a) (1) - (5)):**Neither international preliminary examination fee (37 CFR 1.482)
nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO
and International Search Report not prepared by the EPO or JPO\$1000.00International preliminary examination fee (37 CFR 1.482) not paid to
USPTO but International Search Report prepared by the EPO or JPO\$860.00International preliminary examination fee (37 CFR 1.482) not paid to
USPTO but International Search fee (37 CFR 1.445(a)(2)) paid to USPTO\$710.00International preliminary examination fee (37 CFR 1.482) paid to USPTO
but all claims did not satisfy provisions of PCT Article 33(1)-(4)\$690.00International preliminary examination fee (37 CFR 1.482) paid to USPTO
and all claims satisfied provisions of PCT Article 33 (1)-(4)\$100.00**ENTER APPROPRIATE BASIC FEE AMOUNT =**

\$860.00

Surcharge of \$130.00 for furnishing the oath or declaration later than
months from the earliest claimed priority date (37 CFR 1.492 (e)). ☐ 20 ☐ 30

\$

CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE		
Total Claims	33	- 20 =	13	x \$18.00	\$234.00
Independent Claims	3	- 3 =		x \$80.00	\$
MULTIPLE DEPENDENT CLAIM(S) (if applicable)				+\$270.00	\$270.00

TOTAL OF THE ABOVE CALCULATIONS =

\$1364.00

☐ Applicant claims small entity status. See 37 CFR 1.27. The fees indicated above are reduced by 1/2.

\$

SUBTOTAL =

\$1364.00

Processing fee of \$130.00 for furnishing the English translation later than
months from the earliest priority date (37 CFR 1.492(f)). ☐ 20 ☐ 30

\$

TOTAL NATIONAL FEE =

1364.00

Fee for recording the enclosed assignment (37 CFR 1.21 (h)). The assignment must be accompanied by
an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property. +

\$

TOTAL FEES ENCLOSED =

\$1364.00

Amount to be refunded. \$

charged: \$

a. ☒ A check in the amount of \$ 1364.00 to cover the above fees is enclosed.b. ☐ Please charge my Deposit Account No. _____ in the amount of \$ _____ to cover the above
fees.
A duplicate copy of this sheet is enclosed.c. ☒ The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to
Deposit Account No. 06-0916. A duplicate copy of this sheet is enclosed.d. ☐ Fees are to be charged to a credit card. **WARNING:** Information on this form may become public. **Credit card information
should not be included on this form.** Provide credit card information and authorization on PTO-2038.NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137 (a) or (b))
must be filed and granted to restore the application to pending status.**SEND ALL CORRESPONDENCE TO:**Finnegan, Henderson, Farabow, Garrett & Dunner, L.L.P.
1300 I Street, N.W.
Washington, D.C. 20005-3315

SIGNATURE

Ernest F. Chapman, Reg. No. 25,961
NAME/REGISTRATION NO.

DATED: March 1, 2001

09/786033



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re National Stage U.S. Patent Application of)
PCT/US99/20013:)

Applicants:)
Mark H. PAUSCH et al.)

Application No.: 09/786,033) Group Art Unit: Not Yet Assigned

U.S. Filing Date: March 1, 2001) Examiner: Not Yet Assigned

PCT Filing Date: September 1, 1999)

For: METHODS FOR IMPROVING THE FUNCTION OF HETEROLOGOUS
G-PROTEIN COUPLED RECEPTORS

Assistant Commissioner for Patents
Washington, D.C. 20231

PRELIMINARY AMENDMENT

Sir:

Prior to examination of this application, please amend it as follows:

IN THE SPECIFICATION:

Please insert the attached Sequence Listing, pages 1-7, at the end of the application.

REMARKS

By this Preliminary Amendment, the specification is amended to include a Sequence Listing, in accordance with 37 C.F.R. §§ 1.821 - 1.825. No new matter is added by the Sequence Listing.

LAW OFFICES

INNEGAN, HENDERSON,
FARABOW, GARRETT,
& DUNNER, L.L.P.
1300 I STREET, N. W.
WASHINGTON, DC 20005
202-408-4000

09786033-07001

Please grant any extensions of time required to enter this response and charge any additional required fees to our Deposit Account No. 06-0916.

Respectfully submitted,

FINNEGAN, HENDERSON, FARABOW,
GARRETT & DUNNER, L.L.P.

By: _____



Matthew T. Latimer

Reg. No. 44,024

(202) 408-4495

matthew.latimer@finnegan.com

Date: July 3, 2001

LAW OFFICES

FINNEGAN, HENDERSON,
FARABOW, GARRETT,
& DUNNER, L.L.P.
1300 I STREET, N. W.
WASHINGTON, DC 20005
202-408-4000

Rec'd PCT/PTO 01 MAR 2001

METHODS FOR IMPROVING THE FUNCTION OF HETEROLOGOUS
G PROTEIN-COUPLED RECEPTORSSTATEMENT OF RELATED APPLICATIONS

This application hereby claims the benefit of United States provisional application Serial No. 60/098,704 filed September 1, 1998. The entire disclosure of this provisional application is relied upon and incorporated by reference herein.

FIELD OF THE INVENTION

This invention relates to mutant G protein-coupled receptors with improved G-protein coupling and receptor response, host cells expressing such receptors, vectors useful for making such cells, and methods of making and using same.

BACKGROUND OF THE INVENTION

The actions of many extracellular signals, such as neurotransmitters, hormones, odorants, and light, are mediated by a triad of proteins which has been identified in organisms from yeast to mammals. This triad consists of a receptor, coupled to a trimeric guanine nucleotide-binding regulatory protein (G protein), which in turn is coupled to a cellular effector. These receptors have seven transmembrane domains and are named for their association with the G protein as "G protein-coupled receptors" ("GPCRs").

The regulatory G proteins are comprised of three subunits: a guanylnucleotide binding α subunit; a β subunit; and a γ subunit. *B.R. Conklin and H.R. Bourne (1993)*. G proteins cycle between two forms, depending on whether GDP or GTP is bound to the α subunit. When GDP is bound, the G protein exists as a heterotrimer, the $G\alpha\beta\gamma$ complex. When GTP is bound, the α subunit dissociates, leaving a $G\beta\gamma$ complex. Importantly, when a $G\alpha\beta\gamma$ complex operatively associates with an activated G protein coupled receptor in a cell membrane, the rate of exchange of GTP for bound GDP is increased and, hence, the rate of disassociation of the bound $G\alpha$ subunit from the $G\beta\gamma$ complex increases. The free $G\alpha$ subunit and $G\beta\gamma$ complex are capable of transmitting a signal to downstream elements of a variety of signal transduction pathways. Examples of these downstream cellular effector proteins include, among others, adenylate cyclases, ion channels, and phospholipases. This

- 2 -

fundamental scheme of events forms the basis for a multiplicity of different cell signaling phenomena. *H.G. Dohlman et al. (1991).*

Because of their ubiquitous nature in important biochemical pathways, the G protein-coupled receptors represent important targets for new therapeutic drugs. In turn, the discovery of such drugs will necessarily require screening assays of high specificity and throughput termed high-throughput screening (HTS) assays. Screening assays utilizing microorganisms, such as yeast strains, genetically modified to accommodate functional expression of the G protein-coupled receptors offer significant advantages in research involving ligand binding to numerous receptors implicated in various disease states.

However, microorganisms transformed with wild-type receptors may perform poorly in growth assays, exhibiting, for example, the inability to interact with the heterotrimeric G protein, inappropriate localization and/or desensitization. Many GPCRs are phosphorylated in response to chronic and persistent agonist stimulation which often leads to desensitization followed by sequestration or internalization of the receptors. Desensitization of GPCRs causes uncoupling from interaction with heterotrimeric G proteins. This process is mediated by a variety of regulatory receptor protein kinases, including G protein-coupled receptor kinases (GRK), protein kinase A (PKA), protein kinase C (PKC), and casein kinases (CK). Internalization involves removal of GPCRs from the plasma membrane via receptor-mediated endocytosis. Internalized receptors may be recycled back to the cell surface, or delivered to a lysosomal/vacuolar compartment for degradation. The ubiquitin-mediated degradative pathway is also involved in this process. The ultimate result of receptor phosphorylation and sequestration/internalization is often cell growth arrest, which significantly reduces the utility of the genetically modified microorganism in screening assays.

SUMMARY OF THE INVENTION

It is an object of this invention to provide modified G protein-coupled receptors that function well in high throughput screening assays, implemented in any eukaryotic cell, preferably yeast cells. Thus, a first aspect of the present invention is

- 3 -

directed to nucleotide sequences encoding a G protein-coupled receptor which has been modified to improve the function of the GPCR by causing the receptor to couple more efficiently with the heterotrimeric G protein and/or to fail to interact with the cell desensitization and/or sequestration/internalization machinery, and/or to appropriately localize to the plasma membrane. In preferred embodiments, such modifications lead to improved agonist-stimulated growth-promoting ability. One specific modification of the nucleotide sequence encoding a G protein-coupled receptor encompassed by this invention is a mutation in any intracellular domain or membrane region proximal to internal domains. The mutation may be a deletion, including, for example, a point mutation.

This invention is also directed to chimeric GPCRs in which intracellular domains of heterologous GPCRs that provide favorable G protein coupling properties or domains not subject to the yeast cell desensitization and/or sequestration/internalization machinery are used to replace comparable domains in GPCRs of interest. This invention also relates to the modified nucleotide sequences encoding the chimeric GPCRs, to expression vectors comprising the modified nucleotide sequences, and to host cells transformed therewith.

An additional aspect of this invention is an improved method of assaying compounds to determine effects of ligand binding to the mutant or chimeric GPCRs of this invention by measuring the effect of the test compound on cell growth. The mutant GPCRs prevent or reduce the rate of cell growth arrest due to chronic and persistent agonist stimulation, thereby decreasing the number of false negatives that occur with prior art screening methods and/or increasing the sensitivity of the bioassay.

BRIEF DESCRIPTION OF THE DRAWINGS

FIGURE 1A depicts the results of liquid culture assays on yeast cells containing the rat M3 muscarinic acetylcholine receptor (MAR) using MAR agonist carbachol (CCh). Yeast cells containing a M3 MAR with a deletion in the third intracellular loop (IC3Δ) produced an agonist-dependent growth response, while the wild type MAR did not, indicating that the M3 MAR IC3Δ is functional GPCR.

- 4 -

FIGURE 1B depicts the results of liquid culture fluorescence induction assays on yeast cells containing the rat M3 MAR IC3Δ and the FUS2-GFP reporter plasmid using the MAR agonist carbachol (CCh). A dose-dependent increase in the expression of the green fluorescent protein is observed in response to CCh activation of the M3 MAR IC3Δ expressed in yeast.

FIGURE 2 depicts the results of liquid culture assays on yeast cells containing the *Drosophila* muscarinic acetylcholine receptor using the MAR agonist carbachol (CCh). Yeast cells containing a mutated *Drosophila* MAR containing the M3 MAR IC3Δ produced an agonist-dependent growth response while the wild type *Drosophila* MAR lacked an agonist-dependent yeast cell growth response.

FIGURE 3 depicts the results of an agar-based plate bioassay. **FIGURE 3A** shows a robust growth response of yeast cells containing the IC3Δ cholecystokinin CCKB receptor. **FIGURE 3B** shows only limited growth by yeast cells containing the wild type CCKB receptor, indicating that the deletion of a portion of the third intracellular loop of the CCKB receptor improves its function in yeast.

FIGURE 4 depicts yeast cells transformed with rSSTR3 and with rSSTR3ΔIC3. **FIGURE 4A** demonstrates that yeast cells containing p426GPD-rSSTR3 show a weak response to somatostatin (S-14). **FIGURE 4B** demonstrates a much stronger response by yeast cells containing p426GPD-rSSTR3ΔIC3 assayed under similar conditions.

FIGURE 5 depicts the results of liquid culture assays on yeast cells containing wild type IC3Δ human alpha2A adrenergic receptor using the alpha adrenergic receptor full agonist UK14304. Yeast cells containing the wild type and IC3Δ human alpha 2A adrenergic receptor produced a dose-dependent growth response, indicating that the IC3 deletion is functional.

FIGURE 6 depicts the results of liquid culture assays on yeast cells containing wildtype and carboxy terminally truncated rat NT1-neurotensin receptors using the neurotensin receptor agonist AcNT8-13. Truncation of the rat NT1-neurotensin receptor produces an agonist-dependent growth response that is more sensitive than that observed with the wildtype receptor.

- 5 -

FIGURE 7 depicts the results of liquid culture assays on yeast cells containing the *C. elegans* serotonin receptor using serotonin (5HT) to stimulate yeast cells growth. Yeast cells containing a mutated *C. elegans* serotonin receptor containing the M3 MAR IC3Δ produced a 5HT-dependent growth response. The growth response was blocked by addition of the serotonin receptor antagonists lisuride and mianserin.

DETAILED DESCRIPTION OF THE INVENTION

Modified G Protein-Coupled Receptors

Nucleotide sequences encoding G protein-coupled receptors may be modified to improve the function of the GPCR by causing the receptor to couple more efficiently with the heterotrimeric G protein and/or to fail to interact with the cell desensitization and/or sequestration/internalization machinery. Such modifications lead to improved agonist-stimulated yeast cell growth-promoting ability. The improvement of GPCR-G protein coupling and/or elimination of receptor phosphorylation and/or sequestration/internalization in the host cell provides a means to improve the function of wildtype heterologous GPCRs that fail to stimulate a useful yeast cell growth response. Thus, GPCRs that fail to function in their wild type form may be made to work by the methods of this invention.

The improvement of GPCR-G protein coupling and or elimination of receptor phosphorylation and/or sequestration/internalization in the host cell may be assessed by using routine techniques, such as those described in the Examples set forth below or known to those of skill in the art. For example, improvement of the function of a mutated GPCR over wild type may be quantified as an increase in the signal-to-noise ratio and/or in the sensitivity of the liquid bioassay. The signal-to-noise ratio is determined by comparing the agonist-induced growth rate to the growth rate observed in the absence of agonist. A statistically-significant increase in the signal-to-noise ratio resulting from agonist-stimulation of a mutated GPCR over similar values obtained from cells containing a wild type receptor indicates that the function of the mutated GPCR has been improved.

- 6 -

The sensitivity of the liquid bioassay is defined as the agonist concentration necessary to produce a half-maximal growth rate (ED50 or EC50). The sensitivity of the bioassay is increased if a mutated GPCR produces a half-maximal growth rate at an agonist concentration that is less than that required by the wild type GPCR.

Similarly, the more qualitative agar based bioassay will reflect increases in signal-to-noise ratio and/or sensitivity due to agonist stimulation of mutated GPCRs. In the agar based bioassay, signal-to-noise ratio increases are determined by comparing the extent of growth within the agonist induced growth zone resulting from stimulation of mutated and wild type receptor. The sensitivity of the bioassay is proportional to the radius of the growth zone. Since applied compounds diffuse radially from the site of application to the agar, agonist concentration varies with the square of the radius of the growth zone. Thus, a larger zone of growth in response to agonist activation of mutated GPCRs reflects an increase in sensitivity.

Any G protein-coupled receptor may be employed in practicing this invention. Examples of such receptors include, but are not limited to, adenosine receptors, somatostatin receptors, dopamine receptors, cholecystokinin receptors, muscarinic cholinergic receptors, α -adrenergic receptors, β -adrenergic receptors, opiate receptors, cannabinoid receptors, growth hormone releasing factor, glucagon, serotonin receptors, vasopressin receptors, melanocortin receptors, and neurotensin receptors. In certain preferred embodiments, the receptor is a muscarinic acetylcholine receptor and more preferably, the muscarinic acetylcholine receptor is of the M3 subtype.

Similarly, any suitable host cell may be transformed with the nucleotide sequences encoding the modified G protein-coupled receptors of this invention. Examples of suitable host cells are yeast cells, mammalian cells, insect cells, and bacterial cells. Preferably, the host cells are yeast cells.

One generalizable method for improving the function of a GPCR expressed in a host cell is by modification or elimination of intracellular domains of the GPCR, such as the third intracellular loop (IC3) sequences of the G protein-coupled receptor. Because the desensitization and internalization machinery acts upon the intracellular domains of the GPCR, elimination of the intracellular domains of the GPCRs produces a more stable receptor expression. This has been demonstrated in

- 7 -

experiments conducted in mammalian cells. Muscarinic acetylcholine receptors, including the M3 subtype, lacking a domain of their third intracellular loop thought to be involved in receptor internalization, are maintained in the plasma membrane to a greater extent than their wild type counterparts. *Moro et al. (1993)*.

Representative embodiments of the invention are described in more detail in the following examples.

Example 1. Functional Expression of A Mutated Rat M3 Muscarinic Acetylcholine Receptor (MAR) in Yeast

The third intracellular loops of GPCRs are thought to interact with and participate in the activation of G proteins upon agonist binding. *J. Wess (1997)*. Mutations in IC3 of the yeast mating pheromone receptors, Ste2 and Ste3 have profound effects on coupling the G proteins. *C. Boone et al. (1993)* and *C. Clark et al. (1994)*. Importantly, deletion of portion of the IC3 of mammalian MARs, in particular the rat M3 MAR, is correlated with improved functional expression in mammalian cells with retention of full ability to couple to the heterotrimeric G protein, Gq ($G\alpha\beta\gamma$). The mutated M3 MAR retains all external loops. Transmembrane domains (TMDs) and internal domains other than the IC3 are unchanged. The IC3, found between 5th and 6th membrane spanning helices, was the only domain modified. The bulk of this domain, 96 amino acids in the center of the IC3 (Ala273-Lys469), were deleted, leaving only 22 amino acids proximal to both the 5th and 6th transmembrane helices. Thus, the third intracellular loop of the MAR containing the IC3 deletion (IC3 Δ) is 44 amino acids in length, compared to 240 amino acids in the IC3 of wild type M3 MAR. The improvement in functional expression may due to elimination of domains known to interact with cellular desensitization mechanisms, allowing more functional MAR to be retained at the cell surface.

In order to test the possibility that this IC3 Δ mutation would also improve functional expression in yeast, the DNA sequences encoding the wild type and IC3 Δ rat M3 MARs were cloned into proximity to the glycerol-phosphate dehydrogenase promoter in the yeast expression plasmid, p426GPD, by standard methods. Rat M3

- 8 -

MAR sequences were amplified by PCR using oligonucleotides containing 5' *Bgl*III (AAAAGATCT AAA ATG TAC CCC TAC GAC GTC CCC) (SEQ ID NO: 1) and 3' *Xho*I (AAA CTCGAG CTA CAA GGC CTG CTC CGG CAC TCG C) (SEQ ID NO: 2) sites. The resulting PCR product was digested with the appropriate restriction endonucleases, purified and ligated into appropriate sites in p426GPD. To form the rat M3 IC3Δ, three M3 MAR fragments were amplified by PCR. An amino-terminal coding fragment was amplified using oligonucleotides containing 5' *Bgl*III (AAAAGATCT AAA ATG TAC CCC TAC GAC GTC CCC) (SEQ ID NO: 1) and 3' *Age*I (ATAGTCATGATGGTG ACCGGT ATGTAAAAGGCAGCGATC) (SEQ ID NO: 3) sites. A carboxy-terminal coding fragment was amplified using oligonucleotides containing 5' *Pml*I (GCCTTCATCAT CACGTG GACCCCCTACACC) (SEQ ID NO: 4) and 3' *Xho*I (AAA CTCGAG CTA CAA GGC CTG CTC CGG CAC TCG C) (SEQ ID NO: 2) sites. An IC3 coding fragment was amplified using oligonucleotides containing 5' *Age*I (CGATCGCTGCCTTTTACTT ACCGGT CACCATCATGACTAT) (SEQ ID NO: 5) and 3' *Pml*I (GTTGTAGGGGGTC CACGTG ATGATGAAGGC) (SEQ ID NO: 6) sites using the M3 IC3Δ sequence. *J. Wess (1997)*. The resulting PCR products were digested with the appropriate restriction endonucleases, purified and ligated into appropriate sites in p426GPD. Plasmids were confirmed by restriction endonuclease mapping and DNA sequencing. Using a conventional lithium acetate transformation procedure, the resulting plasmids were introduced into yeast cells useful for performing assays of GPCR agonist-stimulated growth, such as those described in United States Patent 5,691,188, incorporated herein by reference, including, specifically, the MPY578fc cells described in *Pausch et al. (1998)*.

Yeast cells containing the MARs were assayed in liquid culture using the MAR agonist carbachol (CCh). The cells were cultured overnight in 2 ml SC-glucose-ura medium. The cells were diluted 500 fold in SC-glucose-ura-his, pH 6.8 medium containing 5 mM 3-aminotriazole to decrease basal growth rate. Samples of the cell suspension (180 μl) were dispensed to wells of sterile 96 well microtiter dishes containing 20 μl of serially-diluted samples (10^{-1} - 10^{-8} M) of the muscarinic receptor agonists. The plates were incubated at 30°C for 18 hours with agitation (600

- 9 -

rpm). Growth was monitored by recording increases in OD₆₂₀ using a microplate reader. Assays were conducted in duplicate and growth rate measurements obtained during the logarithmic phase of yeast cell growth. Optical density measurements were analyzed using GraphPad Prism and are presented as the mean \pm SEM and were plotted vs. agonist concentration. As shown in Figure 1, the yeast cells containing the M3 MAR IC3 Δ produced an agonist-dependent growth response, demonstrating that the M3 MAR IC3 Δ is functional, while the wild type MAR is non-functional, as indicated by the lack of agonist-dependent yeast cell growth. The growth response of the M3 MAR IC3 Δ containing cells was dose-dependent giving an EC₅₀ for carbachol (CCh) equal to 3 μ M. This value matches the K_D for CCh obtained in HEK cells (7.9 μ M) and the EC₅₀ for CCh induced IP₃ (inositol triphosphate) accumulation (4.0 μ M), suggesting that the M3 MAR IC3 Δ retains the expected pharmacological properties when expressed in yeast cell membranes. Further, the growth response is blocked by the MAR-specific antagonist, atropine (At).

Alternatively, the response to CCh by yeast cells containing the M3 MAR IC3 Δ may be observed by measuring the agonist-induced increase in fluorescent emission from a green fluorescent protein reporter gene whose expression is stimulated by MAR agonists. Green fluorescent protein (GFP) is a protein from *Aequorea* that is intrinsically fluorescent when expressed in yeast cells. The fluorescence from GFP is detectable in live yeast cells, making it possible to measure the level of its expression without any deleterious treatment of the yeast cells. This feature is particularly advantageous in the reporter gene assays that do not require additional steps to permit its detection. An inducible reporter gene that is useful in detecting the agonist-activation of heterologous GPCRs expressed in yeast utilizes transcriptional promoters that are activated by the mating signal transduction pathway. One such promoter is the *FUS2* promoter. In the absence of agonist stimulation, little or no expression of the *Fus2* protein or any other protein whose expression is directed by the *FUS2* promoter is detectable. After treatment with agonist, transcription from the *FUS2* promoter is induced up to 700 fold, leading to substantial increases in *Fus2* expression or in the expression of any gene product whose expression is placed under control of the *FUS2* promoter. Thus, yeast cell fluorescence resulting from GFP

- 10 -

expression under the control of the *FUS2* promoter from a *FUS2*-GFP reporter gene is only observed after agonist activation of a heterologous GPCR.

In order to produce a GFP reporter gene, DNA sequences encoding the enhanced GFP (EGFP, Clontech), *FUS2* promoter and *FUS2* transcriptional terminator sequences were amplified by PCR. The fragments were assembled into the centromere containing plasmid pRS414 so as to place EGFP expression under control of the pheromone responsive *FUS2* promoter in the centromere containing plasmid pRS414, producing plasmid pMP241. Using a conventional lithium acetate transformation procedure, the resulting plasmids were introduced into yeast cells of the kind described in United States Patent 5,691,188, that are useful for performing assays of GPCR agonist-stimulated growth of cells containing the M3 MAR IC3Δ. Specifically, the plasmids were introduced into the MPY578fc cells described in Pausch et al. (1998).

Yeast cells containing the M3 MAR IC3Δ and the *FUS2*-EGFP reporter plasmid were assayed in liquid culture using the MAR agonist carbachol (CCh). The cells were cultured overnight in 2 ml SC-glucose-ura medium. The cells were washed and diluted 5 fold in SC-glucose-ura-his, pH 6.8 medium containing 5 mM 3-aminotriazole to decrease basal growth rate. Samples of the cell suspension (180 μl) were dispensed to wells of sterile 96 well microtiter dishes containing 20 μl of serially-diluted samples (10^{-1} - 10^{-8} M) of CCh. The plates were incubated at 30°C for 6 hours with agitation (600 rpm). Stimulation of the *FUS2*-EGFP reporter gene expression was monitored by recording increases in emission at 530 nm after excitation with 480 nm light using a fluorescence microplate reader. Assays were conducted in duplicate and measurements obtained during the logarithmic phase of yeast cell growth. Fluorescence emission measurements were analyzed using GraphPad Prism and were presented as the mean ± SEM and were plotted vs. agonist concentration. As shown in Figure 1B, the yeast cells containing the M3 MAR IC3Δ produced a dose dependent increase in fluorescence emission, consistent with increased expression of the EGFP from the agonist inducible *FUS2*-GFP reporter gene construct. The EC₅₀ for CCh stimulation of fluorescence emission is 4 μM, identical to values obtained in the growth assay.

- 11 -

Thus, deletion of a portion of the IC3 of the rat M3 MAR has produced a functional GPCR when expressed in yeast, suggesting that modification of internal domains may be a generalizable method for improving the function of heterologous GPCRs expressed in yeast.

Example 2. Functional Expression of a Mutated *D. melanogaster* Muscarinic Acetylcholine Receptor in Yeast

Agonist of the G protein-coupled insect muscarinic acetylcholine receptors (MARs) possess substantial insecticidal and miticidal activity. *M.R. Dick et al. (1997)*. These observations suggest that development of a yeast-based high throughput screen (HTS) for agonists active at insect MARs may be useful in identifying lead compounds that might be developed into insecticides with novel mode of action. Preliminary experiments indicate that the wild type *D. melanogaster* MAR (DMAR), an insect G protein-coupled receptors (GPCRs), is non-functional in yeast. Thus, an effort to develop a method for improving the function of the DMAR in yeast was mounted, via replacement of the DMAR IC3 with the functional IC3 from the M3 MAR IC3A.

In insect cells, the DMAR interacts with the heterotrimeric Gq protein leading to an increase in intracellular calcium in response to muscarinic agonists. One potential explanation for the inactivity of the DMAR in yeast is an inability to efficiently couple to the yeast heterotrimeric G protein. Thus, to devise a method to improve the DMAR function in yeast, selected mutations in the GPCRs that serve to improve functional expression and coupling to the heterotrimeric G protein were examined.

In order to construct the IC3 replacement, PCR fragments encoding three domains were prepared by standard means. Fragment 1 consisted of the amino terminal coding portion of the *Drosophila* MAR up to an *AgeI* site within the 5th TMD, amplified by PCR using oligonucleotides (AAA AGATCT AAA ATG TACGGAAACCAGACGAAC) (SEQ ID NO: 7) and (CCA GTA GAG GAA GCACATGATGGTC AGGCCT AAG TAG AAG GCG GCC AGT GC) (SEQ ID NO: 8). The second fragment of the DMAR was composed of carboxy terminal

- 12 -

coding sequences starting with a *Pm*II site in the 6th TMD, amplified by PCR using oligonucleotides (TTCATCATCACGTGGACTCCGTACAACATC) (SEQ ID NO: 9) and (AAA CTCGAG TTATCTAATTGTAGACGCGGC) (SEQ ID NO: 10). The M3 MAR IC3Δ domain was amplified as an *Age*I-*Pm*II fragment with coding sequence in frame with fragments 1 and 2, described in Example 1. These fragments were assembled in plasmid p426GPD to place the mutated DMAR under control of the GPD promoter. The wild type DMAR was cloned into the expression vector, pMP3, described in United States Patent 5,691,188. Using a conventional lithium acetate transformation procedure, the resulting plasmids were introduced into yeast cells useful for performing assays of GPCR agonist-stimulated growth, such as those described in United States Patent 5,691,188, including, specifically, the MPY578fc cells described in *Pausch et al. (1998)*.

Yeast cells containing the DMAR and the plasmid containing the wild type DMAR were assayed in liquid culture using the MAR agonist carbachol (CCh). The cells were cultured overnight in 2 ml SC-glucose-ura medium. The cells were diluted 500 fold in SC-glucose-ura-his, pH 6.8, medium containing 5 mM 3-aminotriazole to decrease basal growth rate. Samples of the cell suspension (180 μl) were dispensed to wells of sterile 96 well microtiter dishes containing 20 μl of serially-diluted samples (10^{-1} - 10^{-8} M) of the muscarinic receptor agonists. The plates were incubated at 30°C for 18 hours with agitation (600 rpm). Growth was monitored by recording increases in OD620 using a microplate reader. Assays were conducted in duplicate and growth rate measurements obtained during the logarithmic phase of yeast cell growth. Optical density measurements were analyzed using GraphPad Prism and are presented as the mean ± SEM and were plotted vs. agonist concentration. As shown in Figure 2, the yeast cells containing the mutated DMAR, i.e., the M3 MAR IC3Δ, produced an agonist-dependent growth response, demonstrating that the DMAR-M3 MAR IC3Δ is functional. The wild type DMAR is non-functional, as indicated by the lack of agonist-dependent yeast cell growth.

Thus, replacing IC3 of the DMAR with the functional deleted IC3 from the rat M3 MAR produces a functional chimeric GPCR when expressed in yeast, indicating that this method of replacing internal domains may be a generalizable method for

- 13 -

improving the functional expression of heterologous GPCRs in cell-based assays, such as yeast assays.

Example 3. Functional Expression of a Mutated Rat Cholecystokinin CCKB Receptor in Yeast

As shown in Examples 1 and 2, deletion of portion of the IC3 of mammalian MARs, in particular the rat M3 MAR, is correlated with improved functional expression in mammalian and yeast cells with retention of full ability to couple to the heterotrimeric G protein. In order to test the possibility that this IC3Δ mutation would also improve functional expression of other GPCRs in yeast, the DNA sequences encoding the rat wild type and IC3Δ cholecystokinin CCKB receptor were amplified by PCR and cloned into proximity to the glycerol-phosphate dehydrogenase promoter in yeast expression plasmid, p426GPD, by standard methods. The wild type CCKBR was amplified by PCR using oligonucleotides (ACTTAGATCAAAAAATGGAGCGCTCAAGCTGAACCG) (SEQ ID NO: 11) and (TCCCGTCGACTCAGCCAGGCCCCAGTGTGCTG) (SEQ ID NO: 12). The IC3Δ cholecystokinin CCKB receptor was prepared by fusing two overlapping fragments. Fragment 1 contained amino terminal coding sequences including 22 amino acids proximal to the 5th TMD, amplified by PCR using oligonucleotides (ACTTAGATCAAAAAATGGAGCGCTCAAGCTGAACCG) (SEQ ID NO: 11) and (CGAGGGCCAGGGACTGGCCCCGGCCGGGCCCCGGCTTTGGGTCTCG) (SEQ ID NO: 13). Fragment 2 contained carboxy terminal coding sequences including 22 amino acids proximal to the 6th TMD, amplified by PCR using oligonucleotides (TCCCGTCGACTCAGCCAGGCCCCAGTGTGCTG) (SEQ ID NO: 12) and (CGAGACCCAAAGCCGGGCCCCGGCCGGGCGCCAGTCCCTGGCCCTCG) (SEQ ID NO: 14). The two fragments were fused by amplification by PCR using oligos at 5' and 3' ends of the full length CCKB receptor. Using a conventional lithium acetate transformation procedure, the resulting plasmids were introduced into yeast cells useful for performing assays of GPCR agonist-stimulated growth, such as those described in United States Patent 5,691,188, including, specifically, the MPY578fc cells described in *Pausch et al. (1998)*.

- 14 -

Yeast strains containing wild type and IC3Δ cholecystokinin CCKB receptor were grown overnight in 2 ml synthetic complete liquid medium containing glucose (2%) and lacking uracil (SCD-ura) medium. In this agar-based plate bioassay, molten (50°C) SCD-ura-his agar medium (35 ml, adjusted to pH 6.8 by addition of concentrated KOH or NH₄OH prior to autoclaving) containing 0.5 mM AT (3-aminotriazole) was inoculated with the overnight culture (2 x 10⁴ cells/ml) and poured into square (9 x 9 cm) petri plates. Solutions of CCK agonists in DMSO (1 mM, 10 μl) were applied to the surface of the solidified agar (Upper left: CCK8S; upper right, CCK8US; lower left, CCK5; lower right, CCK4). Compounds applied to the surface of the plate diffused radially from the site of application and bound to CCKB receptors expressed on the surface of cells embedded in the agar, resulting in induction of *FUS1-HIS3* expression. The responding cells formed a dense growth zone readily detectable over the limited growth of cells observed in response to basal *FUS1-HIS3* expression. Plates were incubated at 30°C for 3 days (Figure 3). Figure 3A demonstrates the robust growth response of yeast cells containing the IC3Δ cholecystokinin CCKB receptor, while Figure 3B shows only limited growth by yeast cells containing the wild type CCKB receptor, indicating that the deletion of portion of the third intracellular loop of the CCKB receptor improves its function in yeast.

Example 4. Functional Expression of a Mutated Rat Somatostatin Receptor (SSTR) in Yeast

The third intracellular loop participates in many GPCR functions, including G protein coupling, desensitization and interaction with diverse modifying proteins. Somatostatin receptors are encoded in five subtypes, labeled SSTR1-5. Several amino acids are found in the third intracellular loop of the SSTR3 subtype, but not in the equivalent region of SSTR2 subtype. Since SSTR2 functions efficiently in yeast, deletion of those amino acids from IC3 may impart this functional efficiency upon SSTR3. Thus, 8 amino acids, Gln-Trp-Val-Gln-Ala-Pro-Ala-Cys (SEQ ID NO: 15), were deleted from the third intracellular loop of the rSSTR3 cDNA, enabling more efficient receptor signaling in yeast.

- 15 -

Rat SSTR3 sequences were amplified by PCR using oligonucleotides containing 5' BglII and 3' XhoI sites. The resulting PCR product of approximately 1.3 kb was digested with BglII and XhoI, purified and inserted between the BamHI and XhoI sites in p426GPD to generate the plasmid p426GPD-rSSTR3. Recombinant plasmids were confirmed by restriction endonuclease digestion and DNA sequencing.

Standard PCR reactions were used to amplify the rSSTR3 cDNA to yield two PCR fragments that have 36 bp overlap as follows. PCR insert A of approximate size 750 bp was generated using the 5' Bgl oligonucleotide (AAAAAGATCT AAAATGGCCA CTGTTACCTA T) (SEQ ID NO: 16) and the 3' oligonucleotide CTCAGAGCGG CGTCGCCGCT GACACGAGGG CGCCCG (SEQ ID NO: 17). PCR insert B of approximate size 530 bp was generated using the 5' oligonucleotide GCGCCCTCGT GTCAGCGGCG ACGCCGCTCT GAG (SEQ ID NO: 18) and the 3' XhoI oligonucleotide (AAAACTCGAG TTACAGATGG CTCAGTGTGC T) (SEQ ID NO: 19). PCR fragments A and B were gel purified, annealed and amplified by PCR using the flanking 5' BglII and 3' XhoI oligonucleotides to yield the ~1.3 kb rSSTR3 Δ IC3 PCR product. Following purification and digestion with BglII-XhoI, the rSSTR3 Δ IC3 insert was ligated into BamHI-XhoI sites of p426GPD to generate the plasmid p426GPD-rSSTR3 Δ IC3. Restriction mapping and DNA sequencing confirmed correct reading frame and sequence.

Yeast cells of the type useful for expression of GPCRs, described in United States Patent 5,691,188, were transformed with p426GPD-rSSTR3 and p426GPD-rSSTR3 Δ IC3, using standard procedures. The cells (i.e., the LY296 cells, described in *Price et al. (1995)*) were assayed using the agar-based bioassay format described in Example 3. Samples (10 μ l) of Somatostatin (S-14, 1mM) were applied to the surface of the selective agar medium containing the yeast cells expressing the SSTR3. The plates were incubated for 3 days at 30°C. Yeast cells transformed with p426GPD-rSSTR3 along with pLP82 (containing a G α l/G α i2 chimeric G-protein expression plasmid) showed a weak growth response to S-14 (Figure 4A), whereas a much stronger response was observed when p426GPD-rSSTR3 Δ IC3 was assayed under

- 16 -

similar conditions (Figure 4B). These results indicate that deletion of a portion of the IC3 improves the function of the SSTR3 in yeast.

Example 5. An IC3 deleted Human Alpha2A Adrenergic Receptor

As shown in Examples 1-4, deletion of portion of the IC3 of mammalian GPCRs is correlated with improved functional expression in mammalian and yeast cells with retention of full ability to couple to the heterotrimeric G protein. The mutated MARs, CCKBR, and SSTR3 retain all external loops. Transmembrane domains and internal domains other than the IC3 are unchanged. The IC3, found between 5th and 6th membrane spanning helices, was the only domain modified. The bulk of this domain was deleted leaving only 22 amino acids proximal to both the 5th and 6th transmembrane helices. Thus, IC3 of the GPCRs containing the IC3 deletion (IC3Δ) is 44 amino acids in length. The improvement in functional expression may be due to elimination of domains known to interact with cellular desensitization mechanisms, allowing more functional MAR to be retained at the cell surface.

In order to test the possibility that other IC3Δ mutations would also improve functional expression of other GPCRs in yeast, DNA sequences encoding an IC3Δ human alpha2A adrenergic receptor were amplified by PCR and cloned into proximity to the glycerol-phosphate dehydrogenase promoter in yeast expression plasmid, p426GPD, by standard methods. The IC3Δ human alpha2A adrenergic receptor was prepared by fusing two overlapping fragments. Fragment 1 contained amino terminal coding sequences including 39 amino acids proximal to the 5th TMD, amplified by PCR using oligonucleotides (GGCCAGGATCCAAAAATGGGCTCCCTGCAGCCGGACGC) (SEQ ID NO: 20) and (CGGGCCCCGCGGGCGCTCGGGGCCCAGACCGTTGGGC) (SEQ ID NO: 21). Fragment 2 contained carboxy terminal coding sequences including 41 amino acids proximal to the 6th TMD, amplified by PCR using oligonucleotides (CGGGCGACAGCCTGCCGCGGC) (SEQ ID NO: 22) and (AGCGGTCGACTCACACGATCCGCTTCCTGTCCCC) (SEQ ID NO: 23). The two fragments were fused by amplification by PCR using oligos at 5' and 3' ends of the full length alpha2A adrenergic receptor. Using a conventional lithium acetate

- 17 -

transformation procedure, the resulting plasmids were introduced into yeast cells useful for performing assays of GPCR agonist-stimulated growth, such as those described in United States Patent 5,691,188, including, specifically, the MPY578fc cells described in *Pausch et al. (1998)*.

5 Yeast cells containing the wild type IC3Δ human alpha2A adrenergic receptor were assayed in liquid culture using the alpha adrenergic receptor full agonist UK14304 (RBI) and partial agonist clonidine. The cells were cultured overnight in 2 ml SC-glucose-ura medium. The cells were diluted 500 fold in SC-glucose-ura-his, pH 6.8 medium. Samples of the cell suspension (180 μl) were dispensed to wells of sterile 96 well microtiter dishes containing 20 μl of serially-diluted samples of the adrenergic receptor agonist, UK14304 (10^{-3} - 10^{-10} M). The plates were incubated at 10 30°C for 18 hours with agitation (600 rpm). Growth was monitored by recording increases in OD620 using a microplate reader. Assays were conducted in duplicate and growth rate measurements obtained during the logarithmic phase of yeast cell 15 growth. Optical density measurements were analyzed using GraphPad Prism and are presented as the mean ± SEM and were plotted vs. agonist concentration.

The yeast cells containing the wild type IC3Δ human alpha 2A adrenergic receptor produced a dose-dependent growth response, indicating that this IC3 deletion is functional (Figure 5).

20 **Example 6. Truncation of the Rat Neurotensin NT1 Receptor Causes an Increase in Agonist Sensitivity**

In examples 1-4, modification of the third intracellular loop leads to 25 improvement in functional expression of a variety of heterologous GPCRs expressed in yeast. Agonist induced desensitization of the GPCRs is also mediated in part by GPCR internal domains other than the third intracellular loop, such as the intracellular carboxy-terminal tail.

30 Elimination of the carboxy terminal domains from GPCRs has been shown to improve functional expression in yeast and mammalian cells. Truncation of the carboxy terminal tail of the G protein-coupled alpha mating pheromone receptor expressed in α-mating type yeast cells causes supersensitivity to the presence of

- 18 -

5 mating pheromone (*Reneke et al. (1988); Konopka et al (1988)*). Consistent with these observations, a mutated rat neurotensin NT1 receptor (rNTR1) lacking its carboxy terminal tail is resistant to agonist-induced internalization when expressed in mammalian cells (*Hermans et al. (1996)*).

10 To test whether carboxy-terminal truncation improves the functional response of a heterologous GPCR expressed in yeast, the rat NTR1 was modified by deleting the 52 amino acids that constitute the carboxy terminal tail, leaving a shortened receptor 372 amino acids in length. The coding sequences of the wild type and truncated neurotensin NT1 receptor (rNTR1 C-term Δ), were amplified by PCR using a 5' oligonucleotide primer that specified a common amino-terminal coding sequence (AGTCAGATCTAAGCTT AAAA ATG CAC CTC AAC AGC TCC) (SEQ ID NO: 24) and separate oligos that define the wild type (AGTC AGATCT CTA GTA CAG GGTCTCCC) (SEQ ID NO: 25) and truncated carboxy termini (AGAG AGATCT TTAGCGCCACCCAGGACAAAGGC) (SEQ ID NO: 26). These fragments were
15 cloned into proximity of the PGK promoter in the yeast expression vector pPGK by standard methods (*Y-S. Kang et al. (1990)*). Using a conventional lithium acetate transformation procedure, the resulting plasmids were introduced into yeast cells of the kind described in United States Patent 5,691,188 that are useful for performing assays of GPCR agonist-stimulated growth, including, specifically, the MPY578fc cells described in *Pausch et al. (1998)*.

20 Yeast cells containing the NTR1s were assayed in liquid culture using the NT receptor agonist acetyl neurotensin 8-13 (AcNt8-13). The cells were cultured overnight in 2 ml SC-glucose-ura medium. The cells were diluted 500 fold in SC-glucose-ura-his, pH 6.8 medium containing 2 mM 3-aminotriazole to decrease basal growth rate. Samples of the cell suspension (180 μ l) were dispensed to wells of
25 sterile 96 well microtiter dishes containing 20 μ l of serially-diluted samples (10^{-3} - 10^{-10} M) of AcNt8-13. The plates were incubated at 30°C for 18 hours with agitation (600 rpm). Growth was monitored by recording increases in OD₆₂₀ using a microplate reader. Growth rate measurements were obtained during the logarithmic phase of yeast cell growth. Optical density measurements were analyzed using GraphPad
30 Prism and are presented as the mean \pm SEM and were plotted against agonist

- 19 -

concentration. As shown in Figure 6, the yeast cells containing the NTR1s produced an agonist-dependent growth response demonstrating that both the wild type and carboxy terminally truncated NTR1s were functional. The growth response of the rNTR1 C-term Δ containing cells was dose-dependent giving an EC₅₀ for AcNT8-13 equal to 520 nM. This value is five fold lower than observed for cells expressing the wild type NTR1 (2.1 μ M). The carboxy terminal deletion has produced a rNTR1 that responds to a lower concentration of NTR agonist improving the sensitivity of the yeast bioassay.

Thus, deletion of a portion of the carboxy terminal intracellular domain of the rat NTR1 has produced a functional GPCR with increased agonist sensitivity when expressed in yeast, suggesting that modification of this internal domain is a generalizable method for improving the function of heterologous GPCRs expressed in yeast.

Example 7. Functional Expression of a Mutated *C. elegans* Serotonin Receptor in Yeast

Agonists of the G protein-coupled *C. elegans* serotonin receptor (Ce 5HTR) may possess substantial nematocidal activity. These observations suggest that development of a yeast-based HTS for agonists active at Ce 5HTRs may be useful in identifying lead compounds that might be developed into nematocides with a novel mode of action. Preliminary experiments indicated that the wild type Ce 5HTR was non-functional in yeast. Thus, an effort to develop a method for improving the function of the Ce 5HTR in yeast was mounted, via replacement of the Ce 5HTR IC3 with the functional IC3 from the M3 MAR IC3 Δ .

In order to construct the IC3 replacement, PCR fragments encoding three domains were prepared by standard means. Fragment 1 contains the amino terminal-coding portion of the Ce 5HTR to the intracellular interface of the 5th TMD, amplified by PCR using oligonucleotides (AAAAGATCTAAAATGATCGACGAGACGCTTC) (SEQ ID NO: 27) and (CCGCTTGGTGATCTGACTTCTGGTTTCTGTCCCAGAGGCCTGTAGGCCAGCCAGCTCTTTGGTACGCTTCTCAGTTTCCTTATAGATCTTCCAGTACACGC

- 20 -

AAATTATTGC) (SEQ ID NO: 28). The second fragment of the Ce 5HTR contains carboxy-terminal coding sequences starting proximal to the intracellular interface of the 6th TMD, amplified by PCR using oligonucleotides (AAAAGATCTAAAATGATCGACGAGACGCTTC) (SEQ ID NO: 27) and 3' (GGCCTACAGGCCTCTGGGACAGAAACCAGAAAGTCAGATCACCAAGCGGA AGAGGATGTCGCTCATCAAGGAGAAGAAGGCCGCCAGAACGCTAGCAAT TATTACAGGTAC) (SEQ ID NO: 30). The M3 MAR IC3Δ domain was amplified by PCR as described in Example 1.

These fragments were isolated, mixed and amplified by PCR with 5' (AAAAGATCTAAAATGATCGACGAGACGCTTC) (SEQ ID NO: 27) and 3' (AAAAGATCTAAAATGATCGACGAGACGCTTC) (SEQ ID NO: 27) and 3' (AAAAGATCTAAAATGATCGACGAGACGCTTC) (SEQ ID NO: 27) oligonucleotides. The resulting fragment was digested with appropriate restriction endonucleases and assembled in p426GPD to place the mutated Ce 5HTR under control of the GPD promoter. Using a conventional lithium acetate transformation procedure, the resulting plasmids were introduced into yeast cells useful for performing assays of GPCR agonist-stimulated growth, such as those described in United States Patent 5,691,188, including, specifically, the MPY578fc cells described in *Pausch et al.* 1998.

Yeast cells containing the Ce 5HTR were assayed in liquid culture. The cells were cultured overnight in 2 ml SC-glucose-ura medium. The cells were diluted 500 fold in SC-glucose-ura-his, pH 6.8 medium containing 2 mM 3-aminotriazole to decrease basal growth rate. Samples of the cell suspension (200 μl) were dispensed to wells of sterile 96 well microtiter dishes containing 2.0 μl of serially-diluted samples (10^{-2} - 10^{-9} M) of serotonin (5HT). In similar reactions, the serotonergic antagonists lisuride and mianserin were added to each well at 10 μM. The plates were incubated at 30°C for 18 hours with agitation (600 rpm). Growth was monitored by recording increases in OD620 using a microplate reader. Assays were conducted in duplicate and growth rate measurements were obtained during the logarithmic phase of yeast cell growth. Optical density measurements were analyzed using GraphPad Prism and are presented as the mean ± SEM, plotted vs. agonist concentration. K_i values were

- 21 -

determined using the equation of Cheng and Pruesoff. (*Y. Cheng et al. (1973)*). As shown in Figure 7, the yeast cells containing the mutated Ce 5HTR containing the M3 MAR IC3 Δ produced an agonist-dependent growth response, demonstrating that the Ce 5HTR-M3 MAR IC3 Δ is functional. As expected, the serotonergic antagonists lisuride and mianserin blocked the growth inducing effect of serotonin, demonstrating that the Ce 5HTR exhibits the expected pharmacological properties when expressed in yeast.

Thus, replacing IC3 of the Ce 5HTR with the functional deleted IC3 from the rat M3 MAR produces a functional chimeric GPCR when expressed in yeast, indicating that this method of replacing internal domains may be a generalizable method for improving the functional expression of heterologous GPCRs in cell-based assays, such as yeast assays.

Other embodiments of the invention will be apparent to those skilled in the art from consideration of the specification and practice of the invention disclosed herein. It is intended that the specification and examples be considered as exemplary only, with a true scope and spirit of the invention being indicated by the following claims.

The references cited herein are specifically incorporated by reference in their entirety.

- 22 -

REFERENCES

- C. Boone et al.**, "Mutations That Alter the Third Cytoplasmic Loop of the A-Factor Receptor Lead to a Constitutive and Hypersensitive Phenotype," *Genetics, Proc. Nat'l. Acad. Sci. U.S.A.*, 90:9921-9925 (November 1993).
- M. G. Caron**, "The Guanine Nucleotide Regulatory Protein-Coupled Receptors for Nucleotides, Amino Acids, and Amine Neurotransmitters," *Cell Biology*, 1:159-166 (1989).
- Y. Cheng et al.**, "Relationship between the inhibition constant (K_i) and the concentration of inhibitor which causes 50 per cent inhibition (I_{50}) of an enzymatic reaction," *Biochem. Pharmacol.*, 22: 3099-3108 (1973).
- C. D. Clark et al.**, "Systematic Mutagenesis of the Yeast Mating Pheromone Receptor Third Intracellular Loop," *J. Biol. Chem.*, 269(12):8831-8841 (1994).
- B.R. Conklin and H.R. Bourne**, "Structural Elements of G Alpha Subunits that Interact with G Beta Gamma Receptors, and Effectors," *Cell*, 73:631-641 (1993).
- M. R. Dick et al.**, "Muscarinic Agonists as Insecticides and Acaricides," *Pestic. Sci.*, 49:268-276 (1997).
- H.G. Dohlman et al.**, "Model Systems for the Study of Seven-Transmembrane-Segment Receptors," *Ann. Rev. Biochem.*, 60:653-688 (1991).
- E. Hermans et al.**, "Interaction of the COOH-Terminal Domain of the Neurotensin Receptor with a G Protein Does Not Control the Phospholipase C Activation But is Involved in the Agonist Induced Internalization," *Mol. Pharmacol.*, 49:365-372 (1996).
- Y. S. Kang et al.**, "Effects of Expression of Mammalian G Alpha and Hybrid Mammalian-Yeast G Alpha Proteins on the Yeast Pheromone Response Signal Transduction Pathway," *Mol. Cell. Biol.*, 10(6):2582-2590 (1990).
- J. B. Konopka et al.**, "The C-Terminus of the *S. cerevisiae* Alpha Pheromone Receptor Mediates an Adaptive Response to Pheromone," *Cell*, 54:609-620 (1988).
- M. Krieger et al.**, "Isolation of Chinese Hamster Cell Mutants Defective in the Receptor-Mediated Endocytosis of Low Density Lipoprotein," *J. Mol. Biol.*, 150(2):167-84 (Aug. 1981).
- J. Lameh et al.**, "Hm1 Muscarinic Cholinergic Receptor Internalization Requires a Domain in the Third Cytoplasmic Loop," *J. Biol. Chem.*, 267(19):13406-13412 (1992).

09786033 070304

- 23 -

S. B. Liggett et al., "Sites in the Third Intracellular Loop of the α_{2A} -Adrenergic Receptor Confer Short Term Agonist-Promoted Desensitization," *J. Biol. Chem.*, 267(7):4740-4746 (1992).

O. Moro et al., "Serine- and Threonine-rich Domain Regulates Internalization of Muscarinic Cholinergic Receptors," *J. Biol. Chem.*, 268(10):6862-6865 (1993).

M. H. Pausch et al., "G-Protein-Coupled Receptors in *Saccharomyces Cerevisiae*: High-Throughput Screening Assays for Drug Discovery," *Trends in Biotechnology*, 15:487-494 (1997).

M. H. Pausch et al., "Heterologous G protein-coupled receptors in *Saccharomyces cerevisiae*, Methods for genetic analysis and ligand identification," *Identification and expression of G protein-coupled receptors*, Lynch, K. R., Ed., Wiley-Liss, New York, NY, 196-212 (1998).

L. A. Price et al., "Functional coupling of a mammalian somatostatin receptor to the yeast pheromone response pathway," *Mol. Cell. Biol.* 15, 6188-6195, (1995).

J. E. Reneke et al., "The Carboxy Terminal Segment of the Yeast Alpha Factor Receptor Is a Regulatory Domain," *Cell*, 55:221-234 (1988).

A. B. Tobin et al., "Identification of a Novel Receptor Kinase That Phosphorylates A Phospholipase C-linked Muscarinic Receptor," *J. Biol. Chem.*, 271(7):3907-3916 (1996).

A. B. Tobin et al., "Stimulus-Dependent Phosphorylation of G-Protein-Coupled Receptors by Casein Kinase 1 α ," *J. Biol. Chem.*, 272(33):20844-20849 (1997).

H. Tsuga et al., "Internalization and Down-Regulation of Human Muscarinic Acetylcholine Receptor m2 Subtypes," *J. Biol. Chem.*, 273(9):5323-5330 (1996).

J. Wess, "G-Protein-Coupled Receptors: Molecular Mechanisms Involved in Receptor Activation and Selectivity of G-Protein Recognition," *FASEB J.*, 11: 346-354 (1997).

09786033 09301

- 24 -

We claim:

1. An isolated nucleic acid sequence having a sequence encoding a modified G protein-coupled receptor (GPCR), wherein the modification comprises a mutation in an intracellular domain of the G protein-coupled receptor and results in an improved functional response in a cell-based assay, and wherein the modified G protein-coupled receptor is selected from the group consisting of a muscarinic acetylcholine receptor, a cholecystokinin CCKB receptor, a somatostatin receptor, an alpha 2A adrenergic receptor, and a serotonin receptor.
2. The nucleic acid sequence according to claim 1, wherein the modification promotes agonist stimulated growth, and wherein the agonist is a G protein-coupled receptor agonist.
3. The nucleic acid according to claim 2, wherein the modification results in improved coupling between the receptor and a heterotrimeric G protein or failure of the receptor to interact with cell desensitization or sequestration-internalization machinery or proper plasma membrane localization.
4. The nucleic acid according to claim 1, wherein the mutation is a deletion.
5. The nucleic acid according to claim 4, wherein the deletion is a point mutation.
6. The nucleic acid according to claim 4, wherein the deletion is in the third intracellular loop of the G protein-coupled receptor.
7. The nucleic acid according to claim 6, wherein the G protein-coupled receptor is selected from the group consisting of a muscarinic acetylcholine receptor, a cholecystokinin CCKB receptor, and an alpha 2A adrenergic receptor.
8. The nucleic acid sequence according to claim 1, wherein the serotonin receptor is Ce 5HTR.
9. The nucleic acid sequence according to claim 1, wherein the muscarinic acetylcholine receptor is a rat M3 muscarinic acetylcholine receptor or a *D. melanogaster* muscarinic acetylcholine receptor.
10. The nucleic acid sequence according to claim 1, wherein the cholecystokinin CCKB receptor is a rat cholecystokinin CCKB receptor.

- 25 -

11. The nucleic acid sequence according to claim 1, wherein the somatostatin receptor is a rat somatostatin receptor subtype 3.

12. The nucleic acid sequence according to claim 1, wherein the alpha 2A adrenergic receptor is a human alpha 2A adrenergic receptor.

13. A modified G protein-coupled receptor encoded by the nucleic acid sequence according to claim 1.

14. The G protein-coupled receptor according to claim 13, wherein the deleted third intracellular loop is 44 amino acids in length.

15. A mutant G protein-coupled receptor encoded by the nucleic acid sequence according to claim 10, wherein a sequence Gln-Trp-Val-Gln-Ala-Pro-Ala-Cys (SEQ ID NO:15) is deleted from the third intracellular loop of the mutant G protein-coupled receptor.

16. An isolated nucleic acid having a sequence encoding a chimeric G protein-coupled receptor, wherein the chimeric G protein-coupled receptor comprises a modified intracellular domain of a G protein-coupled receptor that confers an improved functional response to the chimeric G protein-coupled receptor in a cell-based assay.

17. The nucleic acid according to claim 16, wherein the modified intracellular domain is the third intracellular loop.

18. A vector comprising the nucleic acid sequence according to claim 1 or 16.

19. A host cell transformed with a vector according to claim 10.

20. The host cell according to claim 19, further comprising a plasmid comprising an inducible reporter gene.

21. The host cell according to claim 19, wherein the host cell is a eukaryotic cell.

22. The host cell according to claim 21, wherein the eukaryotic cell is a yeast cell.

23. The host cell according to claim 22, further comprising a plasmid comprising an inducible reporter gene.

24. The host cell according to claim 23, wherein the reporter gene is a green fluorescent protein.

09786033-070304
FOE020-EE098260

- 26 -

25. The host cell according to claim 24, wherein the green fluorescent protein is operably linked to a *FUS2* promoter.

26. A method for screening compounds capable of binding to G protein-coupled receptors comprising:

- (a) subjecting the host cell according to claim 19 to a test compound; and
- (b) measuring the effect of the test compound on cell growth.

27. A host cell comprising a heterologous G protein-coupled receptor, wherein the G protein-coupled receptor has a modification that results in an improved functional response of the G protein-coupled receptor in a cell-based assay.

28. The host cell according to claim 27, wherein the modification promotes agonist stimulated growth, and wherein the agonist is a G protein-coupled receptor agonist

29. The host cell according to claim 28, wherein the modification results in improved coupling between the heterologous G protein-coupled receptor and a heterotrimeric G protein or failure of the heterologous G protein-coupled receptor to interact with cell desensitization or sequestration-internalization machinery or proper plasma membrane localization.

30. The host cell according to claim 27, wherein the host cell is a eukaryotic cell.

31. The host cell according to claim 30, wherein the heterologous G protein-coupled receptor is modified at an intracellular domain.

32. The host cell according to claim 31, wherein the intracellular domain is the third intracellular domain.

33. The host cell according to claim 27, wherein the heterologous G protein-coupled receptor is modified at the carboxy terminal tail of the G protein-coupled receptor.

34. The host cell according to claim 31 or 33, wherein the host cell is yeast.

35. The host cell according to claim 34, wherein the modified G protein-coupled receptor is a neurotensin receptor.

36. The host cell according to claim 35, wherein the neurotensin receptor is a rat neurotensin NT1 receptor.

09786033 070304



- 27 -

37. A method for screening compounds capable of binding to G protein-coupled receptors comprising:



- (a) subjecting the host cell according to claim 27 to a test compound; and
- (b) measuring the effect of the test compound on yeast cell growth.

0986033-070304

1 / 5

**FIG. 1A****FIG. 1B**

2 / 5

**FIG. 2****FIG. 5**

3/5



FIG. 3A




FIG. 3B

09786033-070301

4/5



FIG. 4A






FIG. 4B

**FIG. 6**

C. ELEGANS 5HT RECEPTOR

**FIG. 7**



Attorney Docket No. 01142,0102
Application No. 09/786,033

DECLARATION AND POWER OF ATTORNEY

As a below named inventor, I hereby declare that: my residence, post office address and citizenship are as stated below next to my name; I believe I am an original, first, and joint inventor of the subject matter which is claimed and for which a patent is sought on the invention entitled:

METHODS FOR IMPROVING THE FUNCTION OF HETEROLOGOUS G PROTEIN-COUPLED RECEPTORS

the application for which was filed on March 1, 2001, as attorney docket number 01142,0102, and which was accorded United States Application Serial No. 09/786,033. The application is based on PCT International Application Number PCT/US99/20013, which was filed on September 1, 1999, and was amended on December 14, 2000.

I hereby state that I have reviewed and understand the contents of the above-identified application, including the claims. I acknowledge the duty to disclose information which is material to patentability as defined in 37 CFR § 1.56.

I hereby claim foreign priority benefits under 35 U.S.C. § 119(a)-(d) or § 365(b) of any foreign application(s) for patent or inventor's certificate or § 365(a) of any PCT international application(s) designating at least one country other than the United States, listed below and have also identified below any foreign application(s) for patent or inventor's certificate or any PCT International application(s) having a filing date before that of the application(s) of which priority is claimed:

Country	Application Number	Date of Filing	Priority Claimed Under 35 U.S.C. § 119(a)-(d)	
			<input type="checkbox"/> YES	<input type="checkbox"/> NO
			<input type="checkbox"/> YES	<input type="checkbox"/> NO

I hereby claim the benefit under 35 U.S.C. § 119(e) of any United States provisional application(s) listed below:

Application Number	Date of Filing
60/098,704	September 1, 1998

I hereby claim the benefit under 35 U.S.C. § 120 of any United States application(s) or § 365(o) of any PCT International application(s) designating the United States, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT International application(s) in the manner provided by the first paragraph of 35 U.S.C. § 112, I acknowledge the duty to disclose information which is material to patentability as defined in 37 CFR § 1.56, and which became available between the filing date of the prior application(s) and the national or PCT International filing date of this application:

Application Number	Date of Filing	Status (Patented, Pending, Abandoned)

I hereby appoint the following attorneys and agents to prosecute this application and transact all business in the Patent and Trademark Office connected therewith: **FINNEGAN, HENDERSON, FARABOW, GARRETT & DUNNER, L.L.P.**, Douglas B. Henderson, Reg. No. 20,291; Ford F. Farabow, Jr., Reg. No. 20,630; Arthur S. Garrett, Reg. No. 20,338; Donald R. Dunner, Reg. No. 19,073; Brian G. Brunsvold, Reg. No. 22,593; Tipton D. Jennings, IV, Reg. No. 20,645; Jerry D. Voight, Reg. No. 23,020; Laurence R. Hefter, Reg. No. 20,827; Kenneth E. Payne, Reg. No. 23,098; Herbert H. Mintz, Reg. No. 26,691; C. Larry O'Rourke, Reg. No. 26,014; Albert J. Santorelli, Reg. No. 22,610; Michael C. Elmer, Reg. No. 25,857; Richard H. Smith, Reg. No. 20,609; Stephen L. Peterson, Reg. No. 26,325; John M. Romary, Reg. No. 26,331; Bruce C. Zotter, Reg. No. 27,680; Dennis P. O'Reilly, Reg. No. 27,932; Allen M. Sokal, Reg. No. 26,695; Robert D. Bajefsky, Reg. No. 25,387; Richard L. Stroup, Reg. No. 28,478; David W. Hill, Reg. No. 28,220; Thomas L. Irving, Reg. No. 28,619; Charles E. Lipsey, Reg. No. 28,165; Thomas W. Winland, Reg. No. 27,605; Basil J. Lewis, Reg. No. 28,818; Martin I. Fuchs, Reg. No. 28,508; E. Robert Yoches, Reg. No. 30,120; Barry W. Graham, Reg. No. 29,924; Susan Haberman Griffen, Reg. No. 30,907; Richard B. Racine, Reg. No. 30,415; Thomas H. Jenkins, Reg. No. 30,857; Robert E. Converse, Jr., Reg. No. 27,432; Clair X. Mullen, Jr., Reg. No. 20,348; Christopher P. Foley, Reg. No. 31,354; John C. Paul, Reg. No. 30,413; Roger D. Taylor, Reg. No. 28,992; David M. Kelly, Reg. No. 30,953; Kenneth J. Meyers, Reg. No. 25,146; Carol P. Einaudi, Reg. No. 32,220; Walter Y. Boyd, Jr., Reg. No. 31,738; Steven M. Anzalone, Reg. No. 32,095; Jean B. Fordis, Reg. No. 32,984; Barbara C. McCurdy, Reg. No. 32,120; James K. Hammond, Reg. No. 31,964; Richard V. Burgujian, Reg. No. 31,744; J. Michael Jakes, Reg. No. 32,824; Thomas W. Banks, Reg. No. 32,719; Christopher P. Isaac, Reg. No. 32,616; Bryan C. Diner, Reg. No. 32,409; M. Paul Barker, Reg. No. 32,013; Andrew Chanhon Sonu, Reg. No. 33,457; David S. Forman, Reg. No. 33,694; Vincent P. Kovalick, Reg. No. 32,867; James W. Edmondson, Reg. No. 33,871; Michael R. McGurk, Reg. No. 32,045; Joann M. Neth, Reg. No. 36,363; Gerson S. Panitch, Reg. No. 33,751; Cheri M. Taylor, Reg. No. 33,216; Charles E. Van Horn, Reg. No. 40,266; Linda A. Wadler, Reg. No. 33,218; Jeffrey A. Berkowitz, Reg. No. 36,743; Michael R. Kelly, Reg. No. 33,921; James B. Monroe, Reg. No. 33,971; Doris Johnson Hines, Reg. No. 34,629; Allen R. Jensen, Reg. No. 28,224; Lori Ann Johnson, Reg. No. 34,498; and David A. Manspeizer, Reg. No. 37,540; Leslie A. McDonell, Reg. No. 34,872, and Matthew T. Latimer, Reg. No. 44,024. Please address all correspondence to **FINNEGAN, HENDERSON, FARABOW, GARRETT & DUNNER, L.L.P.**, 1300 I Street, N.W., Washington, D.C. 20005, Telephone No. (202) 408-4000.

1005 JUL 01 10:00 AM

Attorney Docket No. 01142,0102
Application No. 09/786,033

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

Full Name of First Inventor: <u>Mark Henry PAUSCH</u>	Inventor's Signature: <i>Mark Henry Pausch</i>	Date: <u>7-3-01</u>
Residence: <u>Rocky Hill, New Jersey</u>	Citizenship: <u>USA. USX</u>	
Post Office Address: <u>c/o Wyeth-Ayerst Research, CN 8000, Princeton, NJ 08543-0800</u>		
Full Name of Second Inventor: <u>Jürgen WESS</u>	Inventor's Signature: <i>Jürgen Wess</i>	Date: <u>7-2-01</u>
Residence: <u>Bethesda, Maryland</u>	Citizenship: <u>GER. German</u> DEX	
Post Office Address: <u>c/o Laboratory of Bioorganic Chemistry, NIH-NIDDK, Building 2A, Room B1A-05, 9000 Rockville Pike, Bethesda, Maryland 20892</u>		

09786033-070301
2-00



1

SEQUENCE LISTING

<110> Pausch, Mark Henry
Wess, Jurgen

<120> METHODS FOR IMPROVING THE FUNCTION OF HETERLOGOUS G
PROTEIN-COUPLED RECEPTORS

<130> 01142.0102-00304

<140> PCT/US99/20013

<141> 1999-09-01

<160> 30

<170> PatentIn Ver. 2.1

<210> 1

<211> 33

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:
oligonucleotide

<400> 1

aaaagatcta aaatgtaccc ctacgacgtc ccc

33

<210> 2

<211> 34

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:
oligonucleotide

<400> 2

aaactcgagc tacaaggcct gctccggcac tcgc

34

<210> 3

<211> 39

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:
oligonucleotide

<400> 3

atagtcatga tgggtgaccgg tatgtaaaag gcagcgatc

39

<210> 4

<211> 30

0096603.00304

<212> DNA
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:
oligonucleotide

<400> 4

gccttcatca tcacgtggac cccctacacc

30

<210> 5

<211> 40

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:
oligonucleotide

<400> 5

cgatcgctgc cttttactta ccggtcacca tcatgactat

40

<210> 6

<211> 30

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:
oligonucleotide

<400> 6

gttgtagggg gtccacgtga tgatgaaggc

30

<210> 7

<211> 33

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:
oligonucleotide

<400> 7

aaaagatcta aaatgtacgg aaaccagacg aac

33

<210> 8

<211> 51

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:
oligonucleotide

09766033 070301

<400> 8
ccagtagagg aagcacatga tggtcaggcc taagtagaag gcggccagtg c 51

<210> 9
<211> 30
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:
oligonucleotide

<400> 9
ttcatcatca cgtggactcc gtacaacatc 30

<210> 10
<211> 30
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:
oligonucleotide

<400> 10
aaactcgagt tatctaattg tagacgcggc 30

<210> 11
<211> 36
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:
oligonucleotide

<400> 11
acttagatca aaaaatggag cgctcaagct gaaccg 36

<210> 12
<211> 32
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:
oligonucleotide

<400> 12
tcccgtagac tcagccaggc cccagtgtgc tg 32

<210> 13

09706033 070304

ctcagagcgg cgtcgccgct gacacgaggg cgcccg

36

<210> 18

<211> 33

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:
oligonucleotide

<400> 18

gcgccctcgt gtcagcggcg acgccgtctt gag

33

<210> 19

<211> 31

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:
oligonucleotide

<400> 19

aaaactcgag ttacagatgg ctcaagtgtgc t

31

<210> 20

<211> 38

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:
oligonucleotide

<400> 20

ggccaggatc caaaaatggg ctccctgcag ccggacgc

38

<210> 21

<211> 37

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:
oligonucleotide

<400> 21

cgggcccccgc gggcgctcgg ggcccagacc gttgggc

37

<210> 22

<211> 21

<212> DNA

09786033 070304

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:
oligonucleotide

<400> 22

cgggcgacag cctgccgcgg c

21

<210> 23

<211> 34

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:
oligonucleotide

<400> 23

agcggtcgac tcacacgac cgcttcctgt cccc

34

<210> 24

<211> 38

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:
oligonucleotide

<400> 24

agtcagatct aagcttaaaa atgcacctca acagctcc

38

<210> 25

<211> 27

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:
oligonucleotide

<400> 25

agtcagatct ctagtacagg gtctccc

27

<210> 26

<211> 33

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:
oligonucleotide

090603-0700

33

31

31

```
<400> 30
ggcctacagg cctctgggac agaaaccaga agtcagatca ccaagcggaa gaggatgtcg 60
ctcatcaagg agaagaaggc cgccagaacg ctagcaatta ttacaggtac 110
```

PCT09

RAW SEQUENCE LISTING
 PATENT APPLICATION: US/09/786,033

DATE: 08/01/2001
 TIME: 18:16:24

Input Set : A:\Finnl.app
 Output Set: N:\CRF3\08012001\I786033.raw

ENTERED

3 <110> APPLICANT: Pausch, Mark Henry
 4 Wess, Jorgen
 6 <120> TITLE OF INVENTION: METHODS FOR IMPROVING THE FUNCTION OF HETERLOGOUS G
 7 PROTEIN-COUPLED RECEPTORS
 9 <130> FILE REFERENCE: 01142.102-00304
 C--> 11 <140> CURRENT APPLICATION NUMBER: US/09/786,033
 C--> 12 <141> CURRENT FILING DATE: 2001-07-03
 14 <160> NUMBER OF SEQ ID NOS: 30
 16 <170> SOFTWARE: PatentIn Ver. 2.1
 18 <210> SEQ ID NO: 1
 19 <211> LENGTH: 33
 20 <212> TYPE: DNA
 21 <213> ORGANISM: Artificial Sequence
 23 <220> FEATURE:
 24 <223> OTHER INFORMATION: Description of Artificial Sequence:
 25 oligonucleotide
 27 <400> SEQUENCE: 1
 28 aaaagatcta aaatgtaccc ctacgacgtc ccc 33
 31 <210> SEQ ID NO: 2
 32 <211> LENGTH: 34
 33 <212> TYPE: DNA
 34 <213> ORGANISM: Artificial Sequence
 36 <220> FEATURE:
 37 <223> OTHER INFORMATION: Description of Artificial Sequence:
 38 oligonucleotide
 40 <400> SEQUENCE: 2
 41 aaactcgagc tacaaggcct gctccggcac tcgc 34
 44 <210> SEQ ID NO: 3
 45 <211> LENGTH: 39
 46 <212> TYPE: DNA
 47 <213> ORGANISM: Artificial Sequence
 49 <220> FEATURE:
 50 <223> OTHER INFORMATION: Description of Artificial Sequence:
 51 oligonucleotide
 53 <400> SEQUENCE: 3
 54 atagtcatga tgggtgaccgg tatgtaaaag gcagcgatc 39
 57 <210> SEQ ID NO: 4
 58 <211> LENGTH: 30
 59 <212> TYPE: DNA
 60 <213> ORGANISM: Artificial Sequence
 62 <220> FEATURE:
 63 <223> OTHER INFORMATION: Description of Artificial Sequence:
 64 oligonucleotide
 66 <400> SEQUENCE: 4
 67 gccttcatca tcacgtggac cccctacacc 30
 70 <210> SEQ ID NO: 5
 71 <211> LENGTH: 40

RAW SEQUENCE LISTING

DATE: 08/01/2001

PATENT APPLICATION: US/09/786,033

TIME: 18:16:24

Input Set : A:\Finnl.app

Output Set: N:\CRF3\08012001\I786033.raw

```

72 <212> TYPE: DNA
73 <213> ORGANISM: Artificial Sequence
75 <220> FEATURE:
76 <223> OTHER INFORMATION: Description of Artificial Sequence:
77     oligonucleotide
79 <400> SEQUENCE: 5
80 cgatcgctgc cttttactta ccggtcacca tcatgactat          40
83 <210> SEQ ID NO: 6
84 <211> LENGTH: 30
85 <212> TYPE: DNA
86 <213> ORGANISM: Artificial Sequence
88 <220> FEATURE:
89 <223> OTHER INFORMATION: Description of Artificial Sequence:
90     oligonucleotide
92 <400> SEQUENCE: 6
93 gttgtagggg gtccacgtga tgatgaaggc          30
96 <210> SEQ ID NO: 7
97 <211> LENGTH: 33
98 <212> TYPE: DNA
99 <213> ORGANISM: Artificial Sequence
101 <220> FEATURE:
102 <223> OTHER INFORMATION: Description of Artificial Sequence:
103     oligonucleotide
105 <400> SEQUENCE: 7
106 aaaagatcta aaatgtacgg aaaccagacg aac          33
109 <210> SEQ ID NO: 8
110 <211> LENGTH: 51
111 <212> TYPE: DNA
112 <213> ORGANISM: Artificial Sequence
114 <220> FEATURE:
115 <223> OTHER INFORMATION: Description of Artificial Sequence:
116     oligonucleotide
118 <400> SEQUENCE: 8
119 ccagtagagg aagcacatga tggtcaggcc taagtagaag gcggccagtg c          51
122 <210> SEQ ID NO: 9
123 <211> LENGTH: 30
124 <212> TYPE: DNA
125 <213> ORGANISM: Artificial Sequence
127 <220> FEATURE:
128 <223> OTHER INFORMATION: Description of Artificial Sequence:
129     oligonucleotide
131 <400> SEQUENCE: 9
132 ttcacatca cgtggactcc gtacaacatc          30
135 <210> SEQ ID NO: 10
136 <211> LENGTH: 30
137 <212> TYPE: DNA
138 <213> ORGANISM: Artificial Sequence
140 <220> FEATURE:
141 <223> OTHER INFORMATION: Description of Artificial Sequence:

```


RAW SEQUENCE LISTING

PATENT APPLICATION: US/09/786,033

DATE: 08/01/2001

TIME: 18:16:24

Input Set : A:\Finnl.app

Output Set: N:\CRF3\08012001\I786033.raw

142 oligonucleotide

144 <400> SEQUENCE: 10

145 aaactcgagt tatctaattg tagacgcggc 30

148 <210> SEQ ID NO: 11

149 <211> LENGTH: 36

150 <212> TYPE: DNA

151 <213> ORGANISM: Artificial Sequence

153 <220> FEATURE:

154 <223> OTHER INFORMATION: Description of Artificial Sequence:

155 oligonucleotide

157 <400> SEQUENCE: 11

158 acttagatca aaaaatggag cgctcaagct gaaccg 36

161 <210> SEQ ID NO: 12

162 <211> LENGTH: 32

163 <212> TYPE: DNA

164 <213> ORGANISM: Artificial Sequence

166 <220> FEATURE:

167 <223> OTHER INFORMATION: Description of Artificial Sequence:

168 oligonucleotide

170 <400> SEQUENCE: 12

171 tcccgctcgac tcagccaggc cccagtgtgc tg 32

174 <210> SEQ ID NO: 13

175 <211> LENGTH: 45

176 <212> TYPE: DNA

177 <213> ORGANISM: Artificial Sequence

179 <220> FEATURE:

180 <223> OTHER INFORMATION: Description of Artificial Sequence:

181 oligonucleotide

183 <400> SEQUENCE: 13

184 cgagggccag ggactggccc cgccggggcc cggctttggg tctcg 45

187 <210> SEQ ID NO: 14

188 <211> LENGTH: 45

189 <212> TYPE: DNA

190 <213> ORGANISM: Artificial Sequence

192 <220> FEATURE:

193 <223> OTHER INFORMATION: Description of Artificial Sequence:

194 oligonucleotide

196 <400> SEQUENCE: 14

197 cgagacccaa agccggggccc ggccggggcc agtccctggc cctcg 45

200 <210> SEQ ID NO: 15

201 <211> LENGTH: 8

202 <212> TYPE: PRT

203 <213> ORGANISM: Rattus sp.

205 <400> SEQUENCE: 15

206 Gln Trp Val Gln Ala Pro Ala Cys

207 1 5

210 <210> SEQ ID NO: 16

211 <211> LENGTH: 31

212 <212> TYPE: DNA

RAW SEQUENCE LISTING

DATE: 08/01/2001

PATENT APPLICATION: US/09/786,033

TIME: 18:16:24

Input Set : A:\Finnl.app

Output Set: N:\CRF3\08012001\I786033.raw

213 <213> ORGANISM: Artificial Sequence
 215 <220> FEATURE:
 216 <223> OTHER INFORMATION: Description of Artificial Sequence:
 217 oligonucleotide
 219 <400> SEQUENCE: 16
 220 aaaaagatct aaaatggcca ctgttaccta t 31
 223 <210> SEQ ID NO: 17
 224 <211> LENGTH: 36
 225 <212> TYPE: DNA
 226 <213> ORGANISM: Artificial Sequence
 228 <220> FEATURE:
 229 <223> OTHER INFORMATION: Description of Artificial Sequence:
 230 oligonucleotide
 232 <400> SEQUENCE: 17
 233 ctcagagcgg cgtcgccgct gacacgaggg cgccccg 36
 236 <210> SEQ ID NO: 18
 237 <211> LENGTH: 33
 238 <212> TYPE: DNA
 239 <213> ORGANISM: Artificial Sequence
 241 <220> FEATURE:
 242 <223> OTHER INFORMATION: Description of Artificial Sequence:
 243 oligonucleotide
 245 <400> SEQUENCE: 18
 246 gcgccctcgt gtcagcggcg acgcccgtct gag 33
 249 <210> SEQ ID NO: 19
 250 <211> LENGTH: 31
 251 <212> TYPE: DNA
 252 <213> ORGANISM: Artificial Sequence
 254 <220> FEATURE:
 255 <223> OTHER INFORMATION: Description of Artificial Sequence:
 256 oligonucleotide
 258 <400> SEQUENCE: 19
 259 aaaactcgag ttacagatgg ctcagtgtgc t 31
 262 <210> SEQ ID NO: 20
 263 <211> LENGTH: 38
 264 <212> TYPE: DNA
 265 <213> ORGANISM: Artificial Sequence
 267 <220> FEATURE:
 268 <223> OTHER INFORMATION: Description of Artificial Sequence:
 269 oligonucleotide
 271 <400> SEQUENCE: 20
 272 ggccaggatc caaaaatggg ctccctgcag ccggacgc 38
 275 <210> SEQ ID NO: 21
 276 <211> LENGTH: 37
 277 <212> TYPE: DNA
 278 <213> ORGANISM: Artificial Sequence
 280 <220> FEATURE:
 281 <223> OTHER INFORMATION: Description of Artificial Sequence:
 282 oligonucleotide

RAW SEQUENCE LISTING

DATE: 08/01/2001

PATENT APPLICATION: US/09/786,033

TIME: 18:16:24

Input Set : A:\Finnl.app

Output Set: N:\CRF3\08012001\I786033.raw

284 <400> SEQUENCE: 21
 285 cgggccccgc gggcgctcgg ggcccagacc gttgggc 37
 288 <210> SEQ ID NO: 22
 289 <211> LENGTH: 21
 290 <212> TYPE: DNA
 291 <213> ORGANISM: Artificial Sequence
 293 <220> FEATURE:
 294 <223> OTHER INFORMATION: Description of Artificial Sequence:
 295 oligonucleotide
 297 <400> SEQUENCE: 22
 298 cgggagacag cctgccgcgg c 21
 301 <210> SEQ ID NO: 23
 302 <211> LENGTH: 34
 303 <212> TYPE: DNA
 304 <213> ORGANISM: Artificial Sequence
 306 <220> FEATURE:
 307 <223> OTHER INFORMATION: Description of Artificial Sequence:
 308 oligonucleotide
 310 <400> SEQUENCE: 23
 311 agcgggtcgac tcacacgatc cgcttcctgt cccc 34
 314 <210> SEQ ID NO: 24
 315 <211> LENGTH: 38
 316 <212> TYPE: DNA
 317 <213> ORGANISM: Artificial Sequence
 319 <220> FEATURE:
 320 <223> OTHER INFORMATION: Description of Artificial Sequence:
 321 oligonucleotide
 323 <400> SEQUENCE: 24
 324 agtcagatct aagcttaaaa atgcacctca acagctcc 38
 327 <210> SEQ ID NO: 25
 328 <211> LENGTH: 27
 329 <212> TYPE: DNA
 330 <213> ORGANISM: Artificial Sequence
 332 <220> FEATURE:
 333 <223> OTHER INFORMATION: Description of Artificial Sequence:
 334 oligonucleotide
 336 <400> SEQUENCE: 25
 337 agtcagatct ctagtacagg gtctccc 27
 340 <210> SEQ ID NO: 26
 341 <211> LENGTH: 33
 342 <212> TYPE: DNA
 343 <213> ORGANISM: Artificial Sequence
 345 <220> FEATURE:
 346 <223> OTHER INFORMATION: Description of Artificial Sequence:
 347 oligonucleotide
 349 <400> SEQUENCE: 26
 350 agagagatct ttagcgccac ccaggacaaa ggc 33
 353 <210> SEQ ID NO: 27
 354 <211> LENGTH: 31

VERIFICATION SUMMARY

DATE: 08/01/2001

PATENT APPLICATION: US/09/786,033

TIME: 18:16:25

Input Set : A:\Finnl.app

Output Set: N:\CRF3\08012001\I786033.raw

L:11 M:270 C: Current Application Number differs, Replaced Current Application Number

L:12 M:271 C: Current Filing Date differs, Replaced Current Filing Date

T08012001E093/50